"Theresa has exceptional knowledge and expertise. She is creative and a highly effective negotiator."
— Health Care Client, Chambers USA 2025
Theresa is a nationally recognized health care and pharmaceutical supply chain attorney who advises clients on PBM strategy, drug pricing, and the regulatory and transactional issues shaping the pharmaceutical industry. With more than 25 years of experience, she combines sophisticated legal judgment with deep industry insight to help clients navigate complex commercial, regulatory, and policy environments.
Theresa has extensive experience structuring, drafting, and negotiating transactions across the pharmaceutical supply chain, including PBM service agreements, retail, mail, and specialty pharmacy arrangements, pharmaceutical purchase and distribution agreements, GPO arrangements, and rebate and value-based contracting models. She regularly advises clients on reimbursement structures, drug pricing strategy, and compliance with federal and state fraud and abuse laws.
Her practice spans health care transactions and investment matters, where she represents clients in mergers, private equity and venture capital investments, and strategic collaborations. Theresa supports regulatory diligence, licensing, change-of-ownership filings, and risk assessment across complex health care and pharmaceutical supply chain deals.
Theresa counsels PBMs, health plans, pharmacies, and distribution stakeholders on operational, regulatory, and compliance matters across commercial, Medicare Advantage, Part D, and multistate health care markets. She helps clients evaluate structural design considerations, policy developments, and business opportunities associated with innovation in drug delivery, reimbursement, and emerging service models.
Recognized as an industry thought leader, Theresa frequently communicates timely updates on regulatory, policy, and market developments affecting clients in the pharmaceutical supply chain. She is a regular author and speaker on health care regulatory and PBM-related issues.
Theresa is a member of the firm's Policy Committee.
Experience
- Represented LucyRx, a Summit Partners portfolio company and next-generation pharmacy benefit manager, in connection with multiple strategic growth initiatives, including its strategic combination with Abarca Health, acquisitions of CerpassRx, Integrated Prescription Management (IPM), and HealthSmart’s PBM business, and a strategic PBM affiliation with CitizensRx.
- Represented Cigna as health regulatory counsel in its acquisition of Express Scripts.
- Represented Catamaran (f/k/a CatalystRx) in the structuring and negotiation of its PBM services arrangement with CIGNA.
- Represented national worker’s compensation PBM in connection with multiple workers' compensation PBM acquisitions.
- Represented a national specialty pharmacy provider in connection with an internal compliance audit and investigation and response to government investigation.
- Advised national pharmacy chain in multiple specialty pharmacy and long-term care pharmacy acquisitions.
- Represented SingleCare, a discount medical and pharmacy card operator (DMPO), in its contracting with pharmacies, providers, and other vendors.
- Served as regulatory counsel to a consortium of investors led by TPG Capital and Welsh, Carson, Anderson & Stowe in their $4.1 billion acquisition of Kindred Healthcare, Inc. (NYSE: KND). The transaction was recognized by The Deal as the 2018 Private Equity Deal of the Year.
- Advised a global health care company on a variety of issues in connection with its acquisition of several health plans and provider groups, including health care regulatory due diligence, health care regulatory advice regarding transaction structure and strategy, and preparation of regulatory notices and other filings.
- Advised national pharmacy chain in connection with government agency arrangement to provide accessible COVID-19 testing.
viewpoints
Congress Seeks Answers on Most-Favored-Nation Drug Pricing Agreements and Their Impact on Medicaid
March 20, 2026 | Blog | By Theresa Carnegie, Samantha Hawkins, Grace Callander
The first week of March 2026 brought coordinated congressional oversight targeting the Trump administration's most-favored-nation (MFN) drug pricing initiative. Congressional leaders sent several letters to President Trump and pharmaceutical manufacturers requesting details about the MFN agreements such manufacturers struck with the administration, demonstrating the budding congressional scrutiny of the MFN pricing initiatives, where the impact on patients and state budgets still remains uncertain.
PBM Reform 2026: What Recent Legislation Means for the Industry
March 18, 2026 | Webinar | By Theresa Carnegie, Bridgette Keller, Hassan Shaikh
PBM Reform 2026 explained. Watch this webinar on CAA 2026 PBM changes, DOL proposed rules, FTC enforcement, and compliance priorities.
What PBMs and Group Health Plans Need to Know About the Department of Labor’s Proposed PBM Fee Disclosure Rule
February 9, 2026 | Blog | By Theresa Carnegie, Hassan Shaikh
On January 30, 2026, the Department of Labor released a proposed rule (Proposed Rule) that would end long‑running confusion about how ERISA disclosure obligations apply to PBMs under the Consolidated Appropriations Act, 2021, and give fiduciaries of ERISA‑covered self‑insured group health plans significantly expanded visibility into PBM services and compensation. The proposal pairs broad compensation transparency with comprehensive audit rights covering PBMs and their affiliates, agents, and subcontractors, including PBM‑affiliated brokers and consultants.
The Proposed Rule and the Consolidated Appropriations Act, 2026, both of which were announced last week, will materially impact the PBM industry, particularly PBM’s arrangements with their plan clients. Below we provide an initial summary of the Proposed Rule’s key provisions and discuss its anticipated impact on PBMs, self-insured group health plans, and other stakeholders.
Congress Passes Landmark PBM Reform in 2026 Spending Bill
February 6, 2026 | Blog | By Theresa Carnegie, Bridgette Keller, Hassan Shaikh, Abdie Santiago
On February 3, 2026, Congress passed – and the President signed – the Consolidated Appropriations Act, 2026 (2026 CAA). The legislation includes a long‑anticipated and far‑reaching package of PBM reforms. These reforms draw from the PBM Reform Act of 2025 and other legislative proposals and will significantly reshape PBM operations across the commercial market and Medicare Part D beginning in 2028–2029.
The BALANCE Model and a New Wave of CMS Drug Pricing Models
January 5, 2026 | Blog | By Theresa Carnegie, Hassan Shaikh, Attiya S. Khan, Grace Callander
On December 23, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the Better Approaches to Lifestyles and Nutrition for Comprehensive hEalth (BALANCE) Model, a voluntary, alternative payment model (APM), designed to expand access to GLP-1 medications. At its core, the BALANCE Model intends to promote the use of both GLP-1 medications and lifestyle interventions to help prevent chronic conditions and combat obesity, while also managing the costs of such medications for Medicare and Medicaid beneficiaries and taxpayers.
CMS Targets Rising Drug Costs with New Guard and Globe Pilot Programs
December 23, 2025 | Blog | By Theresa Carnegie, Hassan Shaikh, Stephnie John
CMS proposes two pilot programs: GUARD and GLOBE, to curb Medicare drug costs by tying rebates to international pricing benchmarks. Public comments open until Feb. 23, 2026.
Pharmaceutical Policy in Motion Continued: Trump Inks Nine New Drug Pricing Deals
December 23, 2025 | Blog | By Theresa Carnegie, Attiya S. Khan, Sophia Temis, Stephnie John, Hassan Shaikh
The Trump administration closes 2025 with nine major drug pricing deals, securing discounts on key medications and boosting U.S. pharmaceutical manufacturing investments.
Pharmaceutical Policy in Motion: Updates on the Trump Administration’s Drug Pricing Initiatives
November 13, 2025 | Blog | By Theresa Carnegie, Hassan Shaikh, Stephnie John, Attiya S. Khan, Grace Callander
Since May, the Trump administration has used tariffs and Most Favored Nation (MFN) drug pricing threats as a means to pressure pharmaceutical manufacturers to lower drug prices in the U.S. This pressure culminated in a first-of-its-kind deal with Pfizer.
Since our last update, four other manufacturers have struck deals with the Trump administration aimed at expanding drug access and improving affordability, particularly targeting the GLP-1 and fertility pharmaceutical markets. These agreements reflect the growing consumer demand for GLP-1 drugs and IVF treatments while aligning industry leaders with the federal agenda on health care affordability. In this blog post, we’ll explore the key developments that have followed the Pfizer deal, including how other pharmaceutical companies are responding.
CMS Finalizes Key Requirements for Bona Fide Service Fees in CY 2026 Physician Fee Schedule Rule
November 12, 2025 | Blog | By Theresa Carnegie, Tara E. Dwyer, Rachel Yount
On November 5, 2025, CMS published the CY 2026 Physician Fee Schedule Final Rule (Final Rule), which includes changes to how drug manufacturers must treat Bona Fide Service Fees (BFSFs) in the context of Average Sales Price (ASP) submissions. In the Final Rule, CMS opted not to finalize its proposal to modify the BFSF definition to require fair market value (FMV) methodology standards, FMV reassessments, and independent third-party valuations. This is a notable departure from the proposed rule, which we covered in a prior blog post. However, CMS is moving forward with several important provisions that impact how manufacturers and other stakeholders document and report BFSFs when calculating ASP for Medicare Part B drugs. This update highlights the finalized requirements that stakeholders should now prepare to implement effective January 1, 2026.
Understanding California SB-41: What PBMs Operating in California Need to Know
October 17, 2025 | Blog | By Theresa Carnegie, Hassan Shaikh, Grace Callander
On October 11, 2025, California Governor Gavin Newsom signed Senate Bill 41 (SB-41) into law, introducing a comprehensive set of new regulations for pharmacy benefit managers (PBMs) operating in the state. As part of the broader California Prescription Drug Affordability legislative package, SB-41 reflects the state’s effort to combat high drug costs, standardize PBM pricing practices, enhance transparency, and address concerns around access to pharmacies. Among other things, SB-41 imposes fiduciary obligations on PBMs, establishes fee structure requirements and limitations, prohibits the use of spread pricing and steering to PBM-affiliated pharmacies, and requires 100% passthrough of rebates from PBMs and their affiliates and contracted rebate group purchasing organizations (GPOs) to health plan customers.
News & Press
8 Takeaways from the MHE and Drug Topics Post-Midterms Webinar
November 7, 2026|
CVS’ Drugstores, a Long Familiar Brand, Have Had a Big Problem for Years
November 6, 2026|
FAQ: State PBM Reform in 2026—What's New Since Spring
September 30, 2026|
What to Know About State-Level PBM Reform
June 23, 2026|
Latest PBM Settlement to Reverberate Through Health Plans
April 22, 2026|
PBMs Enter New Era of Legal Scrutiny
February 10, 2026|
Legal Risks Complicate Drugmakers' TrumpRx Participation
February 3, 2026|
Transparency, New Players Shake up PBM Landscape
September 11, 2025|
States Become More Aggressive with PBM Reform
May 30, 2025|
Despite Vaccine Spotlight, RFK Jr. A Health Policy 'Unknown'
November 15, 2024|
HHS Pushes Back on Accumulator Ruling, Prompting Wait-and-See Situation
December 21, 2023|
4 Pharma Industry Arguments Against CMS Drug Pricing Plan
September 29, 2023|
Medicare’s 10-Drug List: The Industry Reacts
August 30, 2023|
Five Mintz Attorneys Named 2020 BTI Client Service All-Stars
December 11, 2020|
Trump Unveils Disputed, Long-Shot Drug Rules Upending System
November 23, 2020|
Mintz Advising Consortium in $4+ Billion Acquisition of Kindred Healthcare
December 21, 2017|
podcasts
Health Law Diagnosed – New Year's Gratitude
February 3, 2025 | Podcast | By Bridgette Keller, Alison H. Peters, Samantha Kingsbury, Theresa Carnegie, Joanne Hawana , Abdie Santiago, Stephnie John, Pamela Polevoy, Karen Lovitch , Jean D. Mancheno, Deborah Daccord, Rachel A. Alexander, Jane Haviland, David Gilboa, Kathryn Edgerton, Hassan Shaikh, Madison Castle, Laurence Freedman, Priyanka Amirneni, Samantha Hawkins, Tara E. Dwyer, Rachel Yount, Sophia Temis, Xavier Hardy
Host Of Counsel Bridgette Keller invites the Mintz Health Law team to reflect on what they’re grateful for as they prepare for the year ahead. Hear from a dynamic group of Members, Of Counsel, and Associates as they share their perspectives on what’s coming up over the horizon.
Mintz Health Law: What We Are Grateful For
January 11, 2023 | Podcast | By Bridgette Keller
Bridgette Keller speaks with the Mintz Health Law team about what they are grateful for as they look back on a year of client service, mentorship, and working together as a team.
Events & Speaking
Regulatory Complexity — Contracts, Transparency, and State-by-State Fragmentation
PBM Contracting Summit 2026
Chicago, IL
AHLA Health Plan and Managed Care Law Institute
Drug Pricing in 2026: Trump Rx and Other Developments
Virtual
New Landmark Pharmacy Benefit Managers Reform: Increased Transparency, Reporting, Federal Oversight, Enforcement
BARBRI Webinar
Virtual
Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance Issues
Strafford Webinar
Virtual
Examining the Impact of COVID-19 on Pharmacy Benefits and the Pharmaceutical Supply Chain
American Health Law Association Annual Meeting
Online Event
4th Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
3rd Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
3rd Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
Pharmacy Benefits and Pharmaceuticals: State of the Industry Update
AHLA
Marriott Chicago Downtown, Magnificent Mile, Chicago, IL
4th Annual Pharmacy Benefit Oversight & Compliance Conference
CBI
16770 North Perimeter Drive Scottsdale, AZ
Recognition & Awards
BTI Consulting Group: Client Service All-Star (2020)
Chambers USA: District of Columbia (Up and Coming) – Healthcare (2014, 2015); District of Columbia – Healthcare (2023 - 2026)
Legal 500 United States: Recognized for Healthcare: Service Providers (2024)
Nightingale’s Healthcare News: Outstanding Young Healthcare Lawyers (2005)
Phi Beta Kappa


